Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Authors
Keywords
-
Journal
Targeted Oncology
Volume 12, Issue 5, Pages 571-597
Publisher
Springer Nature
Online
2017-08-16
DOI
10.1007/s11523-017-0514-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors.
- (2017) J. Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.
- (2017) K. Habben et al. JOURNAL OF CLINICAL ONCOLOGY
- Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
- (2016) Marc A. Becker et al. BMC CANCER
- Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
- (2016) Lucy Ireland et al. CANCER RESEARCH
- Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity
- (2016) Gary K. Schwartz et al. CANCER SCIENCE
- Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer
- (2016) Brittany A. Simone et al. CELL CYCLE
- Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
- (2016) V. M. Macaulay et al. CLINICAL CANCER RESEARCH
- IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models
- (2016) Iris Martinez-Quetglas et al. GASTROENTEROLOGY
- miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway
- (2016) JING HAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
- (2016) Patricia Mucci LoRusso JOURNAL OF CLINICAL ONCOLOGY
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
- (2016) Toshimitsu Yamaoka et al. MOLECULAR CANCER THERAPEUTICS
- Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells
- (2016) J Y Chan et al. ONCOGENE
- Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies
- (2016) H Zhong et al. ONCOGENE
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- (2016) Alberto A. Chiappori et al. ONCOLOGIST
- A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma
- (2016) Peter M. Anderson et al. PEDIATRIC BLOOD & CANCER
- The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
- (2016) D. F. Quail et al. SCIENCE
- Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor
- (2016) Batzaya Davaadelger et al. Oncotarget
- Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
- (2016) Ji Hyun Park et al. Oncotarget
- TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1
- (2016) Shilhav Meisel Sharon et al. Oncotarget
- Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
- (2016) Sung Yong Oh et al. Oncotarget
- IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
- (2016) Ciara H. O’Flanagan et al. Oncotarget
- Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC
- (2016) Hongxin Cao et al. Scientific Reports
- IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
- (2016) Salah-Eddine Lamhamedi-Cherradi et al. JNCI-Journal of the National Cancer Institute
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) C. Parker et al. ANNALS OF ONCOLOGY
- Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
- (2015) Oreekha Amin et al. BMC CANCER
- IGF-IR: a new prognostic biomarker for human glioblastoma
- (2015) C Maris et al. BRITISH JOURNAL OF CANCER
- A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
- (2015) Samuel J. Vidal et al. CANCER CELL
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Maximizing the Efficacy of MAPK-Targeted Treatment in PTEN LOF /BRAF MUT Melanoma through PI3K and IGF1R Inhibition
- (2015) Barbara Herkert et al. CANCER RESEARCH
- Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3
- (2015) Alexey A. Lugovskoy et al. CANCER RESEARCH
- Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
- (2015) W. J. Gradishar et al. CLINICAL CANCER RESEARCH
- InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
- (2015) Y. Ma et al. CLINICAL CANCER RESEARCH
- Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors
- (2015) A. Dasari et al. ENDOCRINE-RELATED CANCER
- Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages
- (2015) James P. Barrett et al. EXPERIMENTAL CELL RESEARCH
- Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion
- (2015) Martin Franz Sprinzl et al. JOURNAL OF HEPATOLOGY
- A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer
- (2015) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer
- (2015) Hye-Young Min et al. Molecular Cancer
- Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
- (2015) Yongik Lee et al. MOLECULAR CARCINOGENESIS
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling
- (2015) E Flashner-Abramson et al. ONCOGENE
- Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling
- (2015) E Sanchez-Lopez et al. ONCOGENE
- Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer
- (2015) Hongxin Cao et al. PLoS One
- IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
- (2015) Eugenia R. Zanella et al. Science Translational Medicine
- ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents
- (2015) Caterina Mancarella et al. Oncotarget
- IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
- (2015) Roger Ramcharan et al. Oncotarget
- Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
- (2015) Varsha P. Brahmkhatri et al. Biomed Research International
- A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer
- (2015) Francesco Sclafani et al. JNCI-Journal of the National Cancer Institute
- IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma
- (2015) Xiaolin Wan et al. NEOPLASIA
- The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link
- (2015) Laura W. Bowers et al. Frontiers in Endocrinology
- Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer
- (2015) Lauren M. Rota et al. Frontiers in Endocrinology
- A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
- (2014) I Brana et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance
- (2014) Alberto S. Pappo et al. CANCER
- Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial
- (2014) Carlos R. Becerra et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
- (2014) J Baselga et al. CANCER RESEARCH
- IGF1R Inhibition in Mammary Epithelia Promotes Canonical Wnt Signaling and Wnt1-Driven Tumors
- (2014) L. M. Rota et al. CANCER RESEARCH
- CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
- (2014) A. M. Heilmann et al. CANCER RESEARCH
- Can we unlock the potential of IGF-1R inhibition in cancer therapy?
- (2014) Helen King et al. CANCER TREATMENT REVIEWS
- Increased miR-223 expression in T cells from patients with rheumatoid arthritis leads to decreased insulin-like growth factor-1-mediated interleukin-10 production
- (2014) M.-C. Lu et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
- (2014) P. Haluska et al. CLINICAL CANCER RESEARCH
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
- (2014) E. Van Cutsem et al. CLINICAL CANCER RESEARCH
- Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
- (2014) R. L. Jones et al. CLINICAL CANCER RESEARCH
- Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
- (2014) S. Di Cosimo et al. CLINICAL CANCER RESEARCH
- Crosstalk between IGF-1R and other Tumor Promoting Pathways
- (2014) Changyu Liu et al. CURRENT PHARMACEUTICAL DESIGN
- Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
- (2014) Viktoria Manstein et al. Current Signal Transduction Therapy
- Insulin-like growth factor-1 induces regulatory T cell-mediated suppression of allergic contact dermatitis in mice
- (2014) B. Johannesson et al. Disease Models & Mechanisms
- Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease
- (2014) D. Bilbao et al. EMBO Molecular Medicine
- The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor
- (2014) Kenichi Suda et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours
- (2014) Haruo Iguchi et al. INVESTIGATIONAL NEW DRUGS
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
- (2014) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
- (2014) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Corey J. Langer et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
- (2014) Claire Corcoran et al. Molecular Cancer
- MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
- (2014) H. Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer
- (2014) Christine M Lovly et al. NATURE MEDICINE
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
- (2014) J. A. Wargo et al. Cancer Discovery
- Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma
- (2014) Tiehong Zhang et al. Scientific Reports
- The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells
- (2014) Roberta Malaguarnera et al. Frontiers in Endocrinology
- Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
- (2013) Nikolaos Ioannou et al. BMC CANCER
- Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro
- (2013) Thomas M Cardillo et al. BMC CANCER
- Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation
- (2013) Leonard Girnita et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
- (2013) I. McCaffery et al. CLINICAL CANCER RESEARCH
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- (2013) S. A. Flanigan et al. CLINICAL CANCER RESEARCH
- IGF2 and cancer
- (2013) Callum Livingstone ENDOCRINE-RELATED CANCER
- Minireview: Nuclear Insulin and Insulin-like Growth Factor-1 Receptors: A Novel Paradigm in Signal Transduction
- (2013) Rive Sarfstein et al. ENDOCRINOLOGY
- An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
- (2013) P. Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation
- (2013) James P. Dean et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
- (2013) Ghassan K. Abou-Alfa et al. JOURNAL OF HEPATOLOGY
- IGF-1R inhibition: right direction, wrong pathway?
- (2013) Sheridan Wilson et al. LANCET ONCOLOGY
- Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
- (2013) John FR Robertson et al. LANCET ONCOLOGY
- Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
- (2013) A. Pavlicek et al. MOLECULAR CANCER THERAPEUTICS
- ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer
- (2013) R. L. Zinn et al. MOLECULAR CANCER THERAPEUTICS
- IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy
- (2013) C. Ferte et al. MOLECULAR CANCER THERAPEUTICS
- Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
- (2013) K. Friedbichler et al. MOLECULAR CANCER THERAPEUTICS
- MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
- (2013) J. B. Fitzgerald et al. MOLECULAR CANCER THERAPEUTICS
- IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination
- (2013) M M Chitnis et al. ONCOGENE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma Identifies CDK4 and IGF1R as Synergistic Drug Targets
- (2013) M. L. Miller et al. Science Signaling
- IGF1 Receptor Signaling Regulates Adaptive Radioprotection in Glioma Stem Cells
- (2013) Satoru Osuka et al. STEM CELLS
- Prognostic and therapeutic relevance of the IGF pathway in Ewing’s sarcoma patients
- (2013) A. C. M. van de Luijtgaarden et al. Targeted Oncology
- Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS -Mutant Lung Cancer
- (2013) Miriam Molina-Arcas et al. Cancer Discovery
- Targeting the insulin-like growth factor-1 receptor in human cancer
- (2013) Alexandre Arcaro Frontiers in Pharmacology
- Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)
- (2012) S. Schmitz et al. ANNALS OF ONCOLOGY
- A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
- (2012) Diane L. Reidy-Lagunes et al. CANCER
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- (2012) A. B. Cortot et al. CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Nonviral-Mediated Hepatic Expression of IGF-I Increases Treg Levels and Suppresses Autoimmune Diabetes in Mice
- (2012) X. M. Anguela et al. DIABETES
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas
- (2012) Irène Asmane et al. EUROPEAN JOURNAL OF CANCER
- Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression
- (2012) Ke Shen et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The decline and fall of the IGF-I receptor
- (2012) Renato Baserga JOURNAL OF CELLULAR PHYSIOLOGY
- Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
- (2012) William D. Tap et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer
- (2012) Andrew Weickhardt et al. Journal of Thoracic Oncology
- BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
- (2012) N. Awasthi et al. MOLECULAR CANCER THERAPEUTICS
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents
- (2012) M Z Lin et al. ONCOGENE
- Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways
- (2012) Farshid Dayyani et al. PLoS One
- Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks
- (2012) Benjamin W. Turney et al. RADIOTHERAPY AND ONCOLOGY
- IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors
- (2012) V. Evdokimova et al. Science Signaling
- Antibody-based therapeutics against components of the IGF system
- (2012) Yang Feng et al. OncoImmunology
- Insulin Analogs and Cancer
- (2012) Laura Sciacca et al. Frontiers in Endocrinology
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
- (2011) J. Gao et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2011) F. Atzori et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies
- (2011) Rachel Steuerman et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
- (2011) Yasushi Goto et al. INVESTIGATIONAL NEW DRUGS
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
- (2011) Alberto S. Pappo et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
- (2011) Heribert Juergens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
- (2011) Suman Malempati et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR /
- (2011) A. Bielen et al. MOLECULAR CANCER THERAPEUTICS
- Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans
- (2011) J. Guevara-Aguirre et al. Science Translational Medicine
- Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
- (2010) B. C. Browne et al. ANNALS OF ONCOLOGY
- Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9
- (2010) Hua Deng et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Complete IGF Signaling Blockade by the Dual-Kinase Inhibitor, BMS-754807, Is Sufficient To Overcome Tamoxifen and Letrozole Resistance In Vitro and In Vivo.
- (2010) P. Haluska et al. CANCER RESEARCH
- Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells
- (2010) T. Aleksic et al. CANCER RESEARCH
- A 3'-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non-Small Cell Lung Cancer in a Chinese Population
- (2010) M. Zhang et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
- (2010) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Insulin-like Growth Factor Receptor 1 (IGF1R) Gene Copy Number Is Associated With Survival in Operable Non–Small-Cell Lung Cancer: A Comparison Between IGF1R Fluorescent In Situ Hybridization, Protein Expression, and mRNA Expression
- (2010) Rafal Dziadziuszko et al. JOURNAL OF CLINICAL ONCOLOGY
- Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer
- (2010) E. Buck et al. MOLECULAR CANCER THERAPEUTICS
- Signatures of mutation and selection in the cancer genome
- (2010) Graham R. Bignell et al. NATURE
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor
- (2010) B. Sehat et al. Science Signaling
- Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells
- (2010) Rive Sarfstein et al. Cancers
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
- (2009) Paul Haluska et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo
- (2009) X. Zeng et al. CLINICAL CANCER RESEARCH
- Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor
- (2009) Mark J Mulvihill et al. Future Medicinal Chemistry
- IGF2Rpolymorphisms and risk of esophageal and gastric adenocarcinomas
- (2009) Cathrine Hoyo et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach
- (2009) Rongshi Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
- (2009) David Olmos et al. LANCET ONCOLOGY
- Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer
- (2009) J. Zha et al. MOLECULAR CANCER THERAPEUTICS
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
- (2009) P. J. Beltran et al. MOLECULAR CANCER THERAPEUTICS
- BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
- (2009) J. M. Carboni et al. MOLECULAR CANCER THERAPEUTICS
- Insulin, insulin-like growth factors and neoplasia
- (2008) Michael Pollak BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- The Type 1 Insulin-Like Growth Factor Receptor Pathway
- (2008) M. M. Chitnis et al. CLINICAL CANCER RESEARCH
- Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
- (2008) Marta Guix et al. JOURNAL OF CLINICAL INVESTIGATION
- IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons
- (2008) S. John Weroha et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started